Although neoadjuvant chemotherapy (NAC) is increasingly used for breast cancer treatment, neoadjuvant endocrine therapy is also administered based on the presence of biomarkers such as estrogen receptor (ER), progesterone receptor (PR) and Ki-67 [1]. This evidence concerns the gene ESR1 and breast carcinoma.